Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News

16:28 EDT 30th March 2017 | BioPortfolio

Showing News Articles 1–25 of 860,000+

Thursday 30th March 2017

NantHealth Reports 72% Increase in Full Year 2016 Total Net Revenue to $100 Million With SaaS Revenue Increasing More Than 181% and Increasing GPS Cancer Adoption

GPS Cancer Adoption by Oncologists Increased in Q4: 264 Oncologists Ordered 1,286 GPS Commercial & Research Tests YTD, with 452 tests in Q4, of which 326 Commercial and 126 Research First Consecutive 100 GPS Cancer Tests Completed at a Single Academic Institution (Feb-Nov 2016) Demonstrating Significant ...

AyoxxA Biosystems GmbH Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 23022017] Prices from USD $250

SummaryAyoxxA Biosystems GmbH AyoxxA is a biotechnology company that provides protein analysis solutions. The company offers a portfolio of disease specific detection kits, human and mouse 6plex cytokine kits, biomarker panel, decoding files, accessory kits and reagents. Its accessory kits comprise analysis suite, control softwares, base frame supplies and relevant components. The company's provid...

Brazil Resectoscopes Market Outlook to 2023 [Updated: 14032017] Prices from USD $4995

Brazil Resectoscopes Market Outlook to 2023SummaryGlobalData's new report, "Brazil Resectoscopes Market Outlook to 2023", provides key market data on the Brazil Resectoscopes market. The report provides value, in millions of US dollars, volume in units and and average prices USD within market segments Rigid Resectoscopes and Resectoscopes Electrodes.The report also provides company shares and dis...

Community Health Systems, Inc. Announces Completion of Tender Offer for 5.125% Senior Secured Notes Due 2018

Community Health Systems, Inc. (the “Company”) (NYSE: CYH) today announced the completion of the previously announced cash tender offer by its wholly owned subsidiary, CHS/Community Health Systems, Inc. (the “Issuer”), for any and all of the Issuer’s outstanding 5.125% Senior Secured Notes due 2018 (the “2018 Notes”). The tender offer expired at ...

Novartis Gains Priority Review from the FDA for its CAR-T Cell Therapy

Basel, March 29, 2017 – Novartis announced today that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) filing and granted priority review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T cell (CAR-T) therapy, in relapsed and refractory (r/r) pediatric and young adult patients with B-cell acute lympho...

Intermountain Healthcare Awarded National 2017 Hearst Health Prize

Hearst Health, a division of Hearst, and the Jefferson College of Population Health of Thomas Jefferson University, have announced that Intermountain Healthcare is the winner of the 2017 Hearst Health Prize. Intermountain was awarded the prize for its Mental Health Integration program, which embeds mental health screening and treatment within primary care ...

Dicerna Reports Fourth Quarter and Full Year 2016 Financial and Operational Results

Management to Host Conference Call Today at 4:30 p.m. ET Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operational results for the fourth quarter and full year ended December 31, 2016. “2016 was an important year for Dicerna...

Dicerna Secures $70 Million in Convertible Preferred Stock Financing

Provides Sufficient Cash into 2019 Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the “Company”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that it has signed a stock purchase agreement with a syndicate of current and new investors, led by Bain Capital Life Sciences, for the sale of rede...

Genmab Discontinues Mid-Stage Non-Hodgkin’s Lymphoma Study

Copenhagen, Denmark; March 30, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its collaboration partner for daratumumab, Janssen Biotech, Inc., has decided not to initiate stage 2 of the Phase II study (CARINA, LYM2001) of daratumumab in three types of relapsed or refractory non-Hodgkin’s lymphoma (NHL).  The study will not proceed to stage …

Lantheus Announces Refinancing of its Debt Facility

Increases available liquidity; positive impact on cash flow projected to be approximately $5 million per year Lantheus Holdings, Inc. (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (collectively, “Lantheus” or “the Compa

FDA Grants Priority Review to Amgen’s Blincyto sBLA

THOUSAND OAKS, Calif., March 29, 2017 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) to include overall survival (OS) data from the Phase 3 TOWER study. The application also includes new data supporting the treatment of ...

Netsmart is First and Only Behavioral Health EHR to Attain ONC Health IT Certification

Netsmart, the largest healthcare IT provider to connect behavioral health and post-acute to the rest of healthcare, announced it is the first and currently, the only behavioral health electronic record (EHR) provider to achieve the

“National Jump in Muddy Puddles Day” (April 1st) Encourages Kids to Jump in Puddles and Get Messy in Honor of Those Who Can’t

Sign up for a Welly Walk Fundraiser for a chance to meet Peppa Pig April showers eventually bring May flowers… but, they also bring muddy puddles! That’s why the founders of the Muddy Puddles Project have declared April 1st “National Jump in Muddy Puddles Day,” kicking-off a season of special events featuring Entertainment One’s (eOne) popular ...

Proveca raises £4m led by Catapult Ventures to launch children’s drug Sialanar in Europe and accelerate children’s medicines pipeline

Manchester, UK – 29th March 2017. Proveca, a European paediatric speciality pharmaceutical company, today announced that it has raised £4m to fund the commercial launch of Sialanar™ and the development and commercialisation of its paediatric product portfolio. Sialanar™ is a treatment for chronic pathological drooling in children, launched in the UK by Proveca, to be follow...

Assembling functional proteins on gold-glass surfaces

Orla Protein Technologies’ Industrial CASE student Tim Robson has presented his latest results on the oriented assembly of engineered outer membrane proteins on the surface of immobilised gold nanoparticles. A poster describing this work was received with great interest at last month’s Biophysical Society Annual Meeting in New Orleans.Orla Protein Technologies have developed a method t...

Engineering Ni supply for biotechnology

Durham scientists have helped uncover the pathway for biosynthesis of the yellow, nickel-containing coenzyme F430, essential in microorganisms that convert CO2 to methane, as reported today in Nature (http://www.nature.com/articles/nature21427.epdf?author_access_token=1SB4HW-XsOmN-OQTqcR039RgN0jAjWel9jnR3ZoTv0PgvILK_Q-fbEftdyVBP50ZNVM7OhS_i5wZdjcf0jkCQJ45wBIcOCglrLCXL5pHhT1qm0tugtMnjEt8o6uhZc1S). ...

No update of the bioeconomy strategy before 2018

Russia Bariatric Surgery Devices Market Outlook to 2023 [Updated: 06032017] Prices from USD $4995

Russia Bariatric Surgery Devices Market Outlook to 2023SummaryGlobalData's new report, "Russia Bariatric Surgery Devices Market Outlook to 2023", provides key market data on the Russia Bariatric Surgery Devices market. The report provides value, in millions of US dollars, volume in units and and average prices USD within market segments Bariatric Stapling Devices, Gastric Bands and Gastric Balloo...

Oncobiologics Inc ONSIU Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 21022017] Prices from USD $250

SummaryOncobiologics Inc Oncobiologics is a biopharmaceutical company that develops, manufactures and commercializes monoclonal antibodies biosimilars in the therapeutic areas of oncology and immunology. The company's ONS3010 is a biosimilar of Humira; and ONS1045 is a biosimilar of Avastin, which is of Phase I trial and Phase 3 trial. Its singleuse technology minimizes manufacturing footprint, an...

South Korea Bariatric Surgery Devices Market Outlook to 2023 [Updated: 06032017] Prices from USD $4995

South Korea Bariatric Surgery Devices Market Outlook to 2023SummaryGlobalData's new report, "South Korea Bariatric Surgery Devices Market Outlook to 2023", provides key market data on the South Korea Bariatric Surgery Devices market. The report provides value, in millions of US dollars, volume in units and and average prices USD within market segments Bariatric Stapling Devices, Gastric Bands and...

Canada Uterine Fibroid Embolization UFE Procedures Outlook to 2023 [Updated: 14032017] Prices from USD $2995

Canada Uterine Fibroid Embolization UFE Procedures Outlook to 2023SummaryGlobalData's new report, "Canada Uterine Fibroid Embolization UFE Procedures Outlook to 2023", provides key procedures data on the Canada Uterine Fibroid Embolization UFE Procedures. The report provides procedure volumes within market segments Gastric Bypass Procedures, Gastric Banding Procedures, Sleeve Gastrectomy Procedur...

Cohera Medical, Inc. Medical Equipment Deals and Alliances Profile [Updated: 14032017] Prices from USD $250

SummaryCohera Medical, Inc. Cohera is a medical device company that designs and develops surgical adhesives and sealants. The company's products include TissuGlu surgical adhesive, and Sylys surgical sealant. Its TissuGlu surgical adhesive is biocompatible for internal use, and forms a bond between tissue layers. Cohera's Sylys surgical sealant is an elastic, resorbable, synthetic sealant designed...

SPRYTE Communications Debuts New Blog for Healthcare Communications Professionals

SPRYTE Insights Will Share Best Practices, Industry Intelligence on Topics Including Media Relations, Referral Marketing and Crisis Communications Philadelphia, PA (PRWEB) March 30, 2017 SPRYTE Communications, a healthcare communications firm, has launched the SPRYTE Insights blog as a resource for communications professionals and those responsible for marketing their healthcare companies and org...

Retro Fitness Flexes Expansion Muscle in Pennsylvania with Plans for 30 New Gyms

Popular Northeast Fitness Franchise Shares Pennsylvania Expansion and Strategic Growth Efforts that will Increase the Brand’s Presence to More than 30 Gyms in the Next Three Years Retro Fitness, a fast-growing, national low-cost, high-value fitness franchise, is targeting the Quaker State for significant expansion. With 17 franchise locations ...

Brain ‘GPS’ Has More Functions Than Previously Thought

ArticleThe part of the brain that creates mental maps to help us navigate may have a larger role in memory and learning that previously believed.


Quick Search
Advertisement
 

BioPortfolio's biotechnology, pharmaceutical, healthcare and medical device information service collates press releases, news articles and blogs from over 275 sources.